Unlock instant, AI-driven research and patent intelligence for your innovation.

Monoclonal neutralizing antibody for resisting human papilloma virus 31 and application of monoclonal neutralizing antibody

An anti-human papilloma, monoclonal antibody technology, used in antiviral agents, antiviral immunoglobulins, applications, etc.

Active Publication Date: 2021-06-08
BEIJING HEALTH GUARD BIOTECH
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The most valent type currently on the market is 9-valent, and there are individual reports of 14-valent vaccines that have been clinically developed, but there are no reports of higher-valent antibodies such as 15-valent specific antibodies.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Monoclonal neutralizing antibody for resisting human papilloma virus 31 and application of monoclonal neutralizing antibody
  • Monoclonal neutralizing antibody for resisting human papilloma virus 31 and application of monoclonal neutralizing antibody
  • Monoclonal neutralizing antibody for resisting human papilloma virus 31 and application of monoclonal neutralizing antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Embodiment 1. Hybridoma cell line development and antibody purification of monoclonal antibody:

[0025] 1. Animal immunity

[0026] 1) Basic immunization: HPV31 L1 VLP antigen was mixed with Freund's complete adjuvant in equal volumes and fully emulsified, subcutaneously injected in points, and a total of 6 mice were immunized, and the injection volume of each Balb / c mouse was 10 μg.

[0027] 2) Booster immunization: The emulsion of antigen and Freund's incomplete adjuvant is used for booster immunization. Three days before cell fusion, saline solution containing 15ug of antigen was injected intraperitoneally. The experimental results are shown in Table 1.

[0028] Table 1 Serum detection of immunized mice (OD450)

[0029]

[0030] It can be seen from the above table that the serum titer of No. 5 mouse is the highest, and the spleen of this mouse was selected for fusion with SP20 cells. That is, mouse No. 5 with the strongest signal was selected for fusion and s...

Embodiment 2 19B4 and 19

[0070] Example 2, Identification of 19B4 and 19C2 Antibodies

[0071] 1. Identification of conformational epitopes of antibodies

[0072] Various types of VLP proteins are processed by alkali denaturation and heat denaturation to destroy the secondary or tertiary structure and preserve the primary structure. Then react with monoclonal antibody and detect it by indirect method ELISA. Through this experiment, not only the recognition status of the antibody to various types of VLPs can be identified, but also whether the antibody is a conformational epitope recognition antibody can be identified. If the OD450 value of the protein denatured and reacted with the monoclonal antibody is significantly reduced, it proves that the monoclonal antibody is a conformational epitope recognition antibody. Recognizing antibodies.

[0073] Experimental procedure: VLP denatured protein treatment: 0.2M sodium carbonate, 0.01M DTT, pH 10.6, incubate at room temperature for 30 minutes and boil f...

Embodiment 3

[0082] Example 3. Preparation of HPV31 VLP Detection Reagent Using 19B4 Purified Antibody

[0083] Using the ELISA double antibody sandwich method, the antibody pairing experiment was carried out. In this example, clone 19B4 was used as the coating antibody, HRP-labeled clone 19C2 was used as the detection antibody, and the ELISA detection method was determined. The test results are shown in Table 11.

[0084] Table 11 Preliminary pairing results of kits

[0085]

[0086] Preliminary pairing experiment results show that the signal of the paired combination detected by 19C2-HRP coated with 19B4 is higher, which is more suitable for ELISA detection. Therefore, this pairing was used for further ELISA detection.

[0087] Detection method: Dilute the coating antibody 19B4 with 0.05 mol / L carbonate buffer solution of pH 9.6 to 10 μg / mL, add 100 μL to each well of the microtiter plate, coat at 4°C overnight, pour off the coating solution, Wash twice with PBST, pat dry, then ad...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a monoclonal neutralizing antibody for resisting a human papilloma virus 31. The monoclonal neutralizing antibody is a 15-valent specific antibody for the human papilloma virus, and can be used for preparing human papilloma virus vaccines, detecting or diagnosing the human papilloma virus, and preparing medicines for preventing and treating diseases caused by the human papilloma virus.

Description

Technical field: [0001] The invention belongs to the technical field of biology and medicine, and specifically relates to a monoclonal neutralizing antibody against human papillomavirus type 31 and an application thereof. Background technique: [0002] Human papillomavirus (HPV) is a non-enveloped double-linked small DNA virus, which mainly invades human epithelial tissue, and then induces various benign and malignant hyperplastic lesions. Certain HPV types are associated with epithelial malignancies such as cervical cancer, laryngeal cancer, bladder cancer, and esophageal cancer. High-risk HPV infection is associated with the occurrence of various malignant tumors. HPV infection has a wide range of epidemics, and the related fatal malignant tumors caused by it are seriously harmful to human health. It is of great significance to develop safe and effective preventive or therapeutic vaccines. Among the vaccines currently on the market, the most valent vaccine is Merck’s 9-v...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/08C12N15/13C12N5/20G01N33/577G01N33/569A61K39/42A61P31/20A61P35/00A61P17/12
CPCC07K16/084G01N33/577G01N33/56983A61P31/20A61P35/00A61P17/12C07K2317/76C07K2317/565C07K2317/51C07K2317/515G01N2333/025G01N2469/10
Inventor 张海江张尧王学红杨增敏李亚坤王艳郑明卉伍树明陈晓刘永江
Owner BEIJING HEALTH GUARD BIOTECH